If you invested $5,000 in this ASX pharmaceuticals stock a year ago, you'd have $34,711 now!

Just how lucky have investors been with this stock?

| More on:
Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's an interesting thing to look back on an ASX stock that you don't own and see a giant that you wish you did own. For one, it usually leads to that sense of regret of not finding that winner sooner, of missing out on the incredible windfall gains that it has showered on to its lucky investors. But it can also renew our resolve to invest in ASX stocks and find the inevitable next winner.

That's what all investors have to confront today when it comes to the Clarity Pharmaceuticals Ltd (ASX: CU6) share price.

This ASX pharmaceutical stock has been an unbridled winner for ASX investors over the past 12 months. A year ago, shares of this company were going for just 88 cents each. Today, those same shares are currently trading for $6.11.

Now that might be down a chunky 2.7% for the day thus far. But Clarity shares still remain up an incredible 594% from where they were this time in 2023.

If it weren't for a rough July so far, this ASX pharmaceuticals stock would be up even higher. As my Fool colleague Bronwyn covered earlier this month, Clarity actually topped out the entire All Ordinaries Index (ASX: XAO) over the 2024 financial year.

This company's shares returned a massive 674.29% over the 12 months to 30 June 2024, rising from 70 cents a share at the start of July 2023 to $5.42 when the markets closed at the end of June.

Despite Clarity's FY2024 success, most of this ASX pharmaceuticals stock's gains came in the back half of the year. In April, to be specific.

Clinical trials behind ASX pharmaceuticals stock's explosive growth

April was the month that Clarity revealed that a prostate cancer patient had a "complete response" to two cycles of Clarity's 67Cu-SAR-bisPSMA treatment, with the patient showing no detectable levels of cancer in the six months following the treatment.

Investors welcomed Clarity's subsequent capital raising, and the ASX pharmaceuticals stock hasn't looked back since.

But let's get down to just how much long-term Clarity investors have banked from this company's gains.

Let's assume our investor managed to spend $5,000 on Clarity shares 12 months ago. As we've established, back on 24 July (22 July last year was a Saturday), Clarity shares closed at 88 cents each. If one had spent $5,000 on this ASX pharmaceuticals stock back then, one would have been able to buy themselves 5,681 shares with some change left over.

If that investor held those 5,681 shares until today, they would be sitting on a Clarity holding worth $34,711 right now. Eat your heart out.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »